Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.93 ▼ -0.02
(-2.26%)
MKT CAP: $14.0M • VOL: 49.1K
52W L $1 52W H $2
ROARABLE / RQD
D • 49/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$1
MEDIAN
$1
MEAN
$1
HIGH
$1
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE BCDA TAPE
BCDA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $1.13 | $1.07 | 2025-02-14 | $0.85 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $1.17 | $1.10 | 2025-02-06 | $0.87 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $1.06 | $1.02 | 2025-01-29 | $0.89 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $0.95 | — | 2025-01-17 | $0.91 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $0.82 | $0.88 | 2025-01-09 | $0.83 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $1.11 | $0.97 | 2024-12-18 | $0.81 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $0.90 | $0.94 | 2024-12-04 | $0.86 | -4.3% | 48% | C |